Literature DB >> 16729480

[Tuberculosis miliar in a patient treated with intravesical instillations of bacillus Calmette-Guérin].

Y Del Castillo Duran1, F Santos Bodí, D Castander Serentill, P Jubert Montaperto, P Espinosa Valencia, C Rabassó Sole.   

Abstract

Tuberculosis miliar is a very rare complication of bacillus Calmette-Guérin (BCG) immunotherapy that is associated to high mortality. Thus, early diagnosis and treatment is essential. At present, there is a polymerase chain reaction technique (PCR) which is a rapid diagnostic method with elevated sensitivity. Treatment with tuberculostatic agents should be initiated as soon as possible, the combination of corticosteroids and cycloserine in serious cases being advisable. A case of a 75 year old patient with intravesical BCG instillations after a transurethral resection of bladder cancer is presented. He was admitted to the Intensive Care Unit (ICU) due to severe acute respiratory failure evolving to acute respiratory distress syndrome (ARDS). Mycobacterium bovis DNA was identified by PCR in blood samples and bronchoaspirate (BAS). He was treated with tuberculostatic agents and corticosteroids, dying due to respiratory failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16729480     DOI: 10.1016/s0210-5691(06)74485-0

Source DB:  PubMed          Journal:  Med Intensiva        ISSN: 0210-5691            Impact factor:   2.491


  2 in total

1.  Subclinical miliary Mycobacterium bovis following BCG immunotherapy for transitional cell carcinoma of the bladder.

Authors:  Chang-Ho Ryan Choi; Sang Oh Lee; Geoff Smith
Journal:  BMJ Case Rep       Date:  2014-05-08

Review 2.  Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

Authors:  María Asunción Pérez-Jacoiste Asín; Mario Fernández-Ruiz; Francisco López-Medrano; Carlos Lumbreras; Ángel Tejido; Rafael San Juan; Ana Arrebola-Pajares; Manuel Lizasoain; Santiago Prieto; José María Aguado
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.